Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Randomized study of induction with bendamustine-rituximab ± bortezomib and maintenance with rituximab ± lenalidomide for MCL

Blood (2024) 144 (10): 1083–1092.

https://doi.org/10.1182/blood.2024023962

Published: 2024

Includes: Supplemental data

Journal Articles

Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma

Muhammad A. Mir, Matthew J. Maurer, Steven C. Ziesmer, Susan L. Slager, Thomas Habermann, William R. Macon, Brian K. Link, Sergei Syrbu, Thomas Witzig, Jonathan W. Friedberg, Oliver Press, Michael LeBlanc, James R. Cerhan, Anne Novak, Stephen M. Ansell

Blood (2015) 125 (6): 992–998.

https://doi.org/10.1182/blood-2014-06-583369

Published: 2015

Includes: Supplemental data

Journal Articles

Single-Agent Lenalidomide for Patients with Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma Who Had Received Prior Stem Cell Transplant.

Julie M. Vose, M.D., Thomas Habermann, Myron S Czuczman, Pier Luigi Zinzani, Craig B. Reeder, MD, Joseph Tuscano, MD, Izidore S Lossos, MD, Dennis Pietronigro, Annette Ervin-Haynes, Thomas Witzig

Blood (2009) 114 (22): 2699.

https://doi.org/10.1182/blood.V114.22.2699.2699

Published: 2009

Journal Articles

Phase II Trial of Lenalidomide (Revlimid ™ ) with Cyclophosphamide and Dexamethasone (RCd) for Newly Diagnosed Myeloma

Blood (2008) 112 (11): 91.

https://doi.org/10.1182/blood.V112.11.91.91

Published: 2008

Journal Articles

Genetic Variation in Genes That Regulate T-Cell Differentiation and Function Is Associated with An Increased Risk of Developing B-Cell Non- Hodgkin Lymphoma

Stephen M. Ansell, Anne Novak, Zhi-Zhang Yang, Zachary S. Fredericksen, Alice H. Wang, Neil Kay, Mark Liebow, Ahmet Dogan, Timothy G. Call, Thomas Witzig, Thomas M. Habermann, Susan L. Slager, James R. Cerhan

Blood (2008) 112 (11): 3762.

https://doi.org/10.1182/blood.V112.11.3762.3762

Published: 2008

Journal Articles

Elevated Expression of GPR34 and Its Association with a Novel Translocation T(X;14)(p11;q32) Involving IGHS and GPR34 in MALT Lymphoma.

Anne Novak, Takashi Akasaka, Michelle Manske, Mamta Gupta, Thomas Witzig, Martin JS Dyer, Ahmet Dogan, Ellen Remstein, Stephen Ansell

Blood (2008) 112 (11): 2251.

https://doi.org/10.1182/blood.V112.11.2251.2251

Published: 2008

Journal Articles

Long-Term Results of Single-Agent Thalidomide as Initial Therapy for Asymptomatic (Smoldering or Indolent) Myeloma.

Suzanne Hayman, MD, Morie Gertz, MD, Martha Lacy, MD, Angela Dispenzieri, MD, Rafael Fonseca, MD, Susan Geyer, PhD, Shaji Kumar, MD, Steven Zeldenrust, MD, Stephen Russell, MD, PhD, John Lust, MD, PhD, Robert Kyle, MD, Philip Greipp, MD, Thomas Witzig, MD, S. Vincent Rajkumar, MD

Blood (2006) 108 (11): 3568.

https://doi.org/10.1182/blood.V108.11.3568.3568

Published: 2006

Journal Articles

Lenalidomide Plus Dexamethasone (Rev/Dex) in Newly Diagnosed Myeloma: Response to Therapy, Time to Progression, and Survival.

Martha Lacy, MD, Morie Gertz, MD, Angela Dispenzieri, MD, Suzanne Hayman, MD, Susan Geyer, PhD, Steven Zeldenrust, MD, Shaji Kumar, MD, Philip Greipp, MD, Rafael Fonseca, MD, John Lust, MD, Stephen Russell, MD, PhD, Robert Kyle, MD, Thomas Witzig, MD, Leif Bergsagel, MD, S. Vincent Rajkumar, MD

Blood (2006) 108 (11): 798.

https://doi.org/10.1182/blood.V108.11.798.798

Published: 2006

Journal Articles

Imaging of Peripheral Blood Mononuclear Cells (PBMC) Trafficking in Patients with Non-Hodgkin’s Lymphoma (NHL) Prior to and Following Therapy.

George Weiner, MD, Gregory Wiseman, MD, Thomas Witzig, MD, Brian Link, MD, James Wooldridge, MD, James Ponto, MD, Malik Juweid, MD

Blood (2005) 106 (11): 2823.

https://doi.org/10.1182/blood.V106.11.2823.2823

Published: 2005

Journal Articles

Absolute Lymphocyte Count and CD4 Count Predict a Superior Progression-Free Survival in Non-Hodgkin Lymphoma Patients Treated with Rituximab and Interleukin-12.

Cristina Joao, MD, Luis F. Porrata, MD, Thomas Witzig, MD, Paul Kurtin, Ivana Micallef, MD, Svetomir N. Markovic, MD, PhD, Charles Erlichman, MD, Anne Novak, Stephen M. Ansell, MD, PhD

Blood (2005) 106 (11): 1495.

https://doi.org/10.1182/blood.V106.11.1495.1495

Published: 2005

Journal Articles

A Preliminary Report of a Phase I Study of Zevalin® Using a Modified Treatment Regimen for Relapsed or Refractory CD20+ B-Cell Follicular or Transformed Non-Hodgkin’s Lymphoma (NHL).

Andres Forero-Torres, MD, Jatin Shah, MD, Stephen Besh, MD, Susan Knox, MD, Ivana Micallef, MD, George Wiseman, M.D, Thomas Witzig, MD, Albert Lobuglio, MD, Sui Shen, PhD, Michael Goris, MD, Jeanne Connor, Ruby Meredith, MD, PhD

Blood (2005) 106 (11): 4798.

https://doi.org/10.1182/blood.V106.11.4798.4798

Published: 2005

Journal Articles

Role of the Chemokine Receptor CXCR4 in Waldenstrom Macroglobulinemia.

Irene M. Ghobrial, MD, Mona Melhem, MD, Ujjal Singha, PhD, Diane George, Michael Timm, MD, Lanie Francis, MD, Yazan Alsayed, MD, Alissa Huston, MD, G. David Roodman, MD, PhD, Philip Greipp, MD, Morie Gertz, MD, Thomas Witzig, MD

Blood (2005) 106 (11): 993.

https://doi.org/10.1182/blood.V106.11.993.993

Published: 2005

Journal Articles

Anti-Tumor Activity of Single-Agent CCI-779 for Relapsed Mantle Cell Lymphoma: A Phase II Trial in the North Central Cancer Treatment Group.

Thomas Witzig, M.D., Susan Geyer, Ph.D., Irene Ghobrial, M.D., David Inwards, M.D., Rafael Fonseca, M.D., Scott Kaufmann, M.D., Ph.D., Paul Kurtin, M.D., Joseph Colgan, M.D., William Morice, M.D., Ph.D., Steven Alberts, M.D., Muhammed Salim, M.D., Kendrith Rowland, M.D., Shaker Dakhil, M.D., Roscoe Morton, M.D., Philip Stella, M.D.

Blood (2004) 104 (11): 129.

https://doi.org/10.1182/blood.V104.11.129.129

Published: 2004

Journal Articles

Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20 + B-cell lymphoma: long-term follow-up of a phase 1/2 study

Leo I. Gordon, Arturo Molina, Thomas Witzig, Christos Emmanouilides, Andrew Raubtischek, Mohamed Darif, Russell J. Schilder, Greg Wiseman, Christine A. White

Blood (2004) 103 (12): 4429–4431.

https://doi.org/10.1182/blood-2003-11-3883

Published: 2004

NARROW

Randomized study of induction with bendamustine-rituximab ± bortezomib and maintenance with rituximab ± lenalidomide for MCL

Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma

Single-Agent Lenalidomide for Patients with Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma Who Had Received Prior Stem Cell Transplant.

Phase II Trial of Lenalidomide (Revlimid ™ ) with Cyclophosphamide and Dexamethasone (RCd) for Newly Diagnosed Myeloma

Genetic Variation in Genes That Regulate T-Cell Differentiation and Function Is Associated with An Increased Risk of Developing B-Cell Non- Hodgkin Lymphoma

Elevated Expression of GPR34 and Its Association with a Novel Translocation T(X;14)(p11;q32) Involving IGHS and GPR34 in MALT Lymphoma.

Long-Term Results of Single-Agent Thalidomide as Initial Therapy for Asymptomatic (Smoldering or Indolent) Myeloma.

Lenalidomide Plus Dexamethasone (Rev/Dex) in Newly Diagnosed Myeloma: Response to Therapy, Time to Progression, and Survival.

Imaging of Peripheral Blood Mononuclear Cells (PBMC) Trafficking in Patients with Non-Hodgkin’s Lymphoma (NHL) Prior to and Following Therapy.

Absolute Lymphocyte Count and CD4 Count Predict a Superior Progression-Free Survival in Non-Hodgkin Lymphoma Patients Treated with Rituximab and Interleukin-12.

A Preliminary Report of a Phase I Study of Zevalin® Using a Modified Treatment Regimen for Relapsed or Refractory CD20+ B-Cell Follicular or Transformed Non-Hodgkin’s Lymphoma (NHL).

Role of the Chemokine Receptor CXCR4 in Waldenstrom Macroglobulinemia.

Anti-Tumor Activity of Single-Agent CCI-779 for Relapsed Mantle Cell Lymphoma: A Phase II Trial in the North Central Cancer Treatment Group.

Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20 + B-cell lymphoma: long-term follow-up of a phase 1/2 study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only